214 related articles for article (PubMed ID: 27405817)
1. PF-05231023, a long-acting FGF21 analogue, decreases body weight by reduction of food intake in non-human primates.
Thompson WC; Zhou Y; Talukdar S; Musante CJ
J Pharmacokinet Pharmacodyn; 2016 Aug; 43(4):411-25. PubMed ID: 27405817
[TBL] [Abstract][Full Text] [Related]
2. A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects.
Talukdar S; Zhou Y; Li D; Rossulek M; Dong J; Somayaji V; Weng Y; Clark R; Lanba A; Owen BM; Brenner MB; Trimmer JK; Gropp KE; Chabot JR; Erion DM; Rolph TP; Goodwin B; Calle RA
Cell Metab; 2016 Mar; 23(3):427-40. PubMed ID: 26959184
[TBL] [Abstract][Full Text] [Related]
3. Once-weekly administration of a long-acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with hypertriglyceridaemia and in non-human primates.
Kim AM; Somayaji VR; Dong JQ; Rolph TP; Weng Y; Chabot JR; Gropp KE; Talukdar S; Calle RA
Diabetes Obes Metab; 2017 Dec; 19(12):1762-1772. PubMed ID: 28573777
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics (PK), pharmacodynamics (PD) and integrated PK/PD modeling of a novel long acting FGF21 clinical candidate PF-05231023 in diet-induced obese and leptin-deficient obese mice.
Weng Y; Chabot JR; Bernardo B; Yan Q; Zhu Y; Brenner MB; Vage C; Logan A; Calle R; Talukdar S
PLoS One; 2015; 10(3):e0119104. PubMed ID: 25790234
[TBL] [Abstract][Full Text] [Related]
5. FGF21 decreases body weight without reducing food intake or bone mineral density in high-fat fed obese rhesus macaque monkeys.
Andersen B; Straarup EM; Heppner KM; Takahashi DL; Raffaele V; Dissen GA; Lewandowski K; Bödvarsdottir TB; Raun K; Grove KL; Kievit P
Int J Obes (Lond); 2018 Jun; 42(6):1151-1160. PubMed ID: 29892039
[TBL] [Abstract][Full Text] [Related]
6. Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats.
Sarruf DA; Thaler JP; Morton GJ; German J; Fischer JD; Ogimoto K; Schwartz MW
Diabetes; 2010 Jul; 59(7):1817-24. PubMed ID: 20357365
[TBL] [Abstract][Full Text] [Related]
7. Mechanistic investigation of the preclinical pharmacokinetics and interspecies scaling of PF-05231023, a fibroblast growth factor 21-antibody protein conjugate.
Giragossian C; Vage C; Li J; Pelletier K; Piché-Nicholas N; Rajadhyaksha M; Liras J; Logan A; Calle RA; Weng Y
Drug Metab Dispos; 2015 Jun; 43(6):803-11. PubMed ID: 25805881
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pharmacodynamics of PF-05231023, a novel long-acting FGF21 mimetic, in a first-in-human study.
Dong JQ; Rossulek M; Somayaji VR; Baltrukonis D; Liang Y; Hudson K; Hernandez-Illas M; Calle RA
Br J Clin Pharmacol; 2015 Nov; 80(5):1051-63. PubMed ID: 25940675
[TBL] [Abstract][Full Text] [Related]
9. FGF21 decreases food intake and body weight in obese Göttingen minipigs.
Christoffersen B; Straarup EM; Lykkegaard K; Fels JJ; Sass-Ørum K; Zhang X; Raun K; Andersen B
Diabetes Obes Metab; 2019 Mar; 21(3):592-600. PubMed ID: 30328263
[TBL] [Abstract][Full Text] [Related]
10. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice.
Xu J; Lloyd DJ; Hale C; Stanislaus S; Chen M; Sivits G; Vonderfecht S; Hecht R; Li YS; Lindberg RA; Chen JL; Jung DY; Zhang Z; Ko HJ; Kim JK; Véniant MM
Diabetes; 2009 Jan; 58(1):250-9. PubMed ID: 18840786
[TBL] [Abstract][Full Text] [Related]
11. A selective cannabinoid-1 receptor antagonist, PF-95453, reduces body weight and body fat to a greater extent than pair-fed controls in obese monkeys.
Wagner JD; Zhang L; Kavanagh K; Ward GM; Chin JE; Hadcock JR; Auerbach BJ; Harwood HJ
J Pharmacol Exp Ther; 2010 Oct; 335(1):103-13. PubMed ID: 20605903
[TBL] [Abstract][Full Text] [Related]
12. A Novel Fc-FGF21 With Improved Resistance to Proteolysis, Increased Affinity Toward β-Klotho, and Enhanced Efficacy in Mice and Cynomolgus Monkeys.
Stanislaus S; Hecht R; Yie J; Hager T; Hall M; Spahr C; Wang W; Weiszmann J; Li Y; Deng L; Winters D; Smith S; Zhou L; Li Y; Véniant MM; Xu J
Endocrinology; 2017 May; 158(5):1314-1327. PubMed ID: 28324011
[TBL] [Abstract][Full Text] [Related]
13. Antiobesity effects of the beta-cell hormone amylin in diet-induced obese rats: effects on food intake, body weight, composition, energy expenditure, and gene expression.
Roth JD; Hughes H; Kendall E; Baron AD; Anderson CM
Endocrinology; 2006 Dec; 147(12):5855-64. PubMed ID: 16935845
[TBL] [Abstract][Full Text] [Related]
14. S 23521 decreases food intake and body weight gain in diet-induced obese rats.
Claret M; Corominola H; Canals I; Nadal B; Chavanieu A; Pfeiffer B; Renard P; Gorostiaga C; Delagrange P; Grassy G; Gomis R
Obes Res; 2004 Oct; 12(10):1596-603. PubMed ID: 15536223
[TBL] [Abstract][Full Text] [Related]
15. Glyco-engineered Long Acting FGF21 Variant with Optimal Pharmaceutical and Pharmacokinetic Properties to Enable Weekly to Twice Monthly Subcutaneous Dosing.
Weng Y; Ishino T; Sievers A; Talukdar S; Chabot JR; Tam A; Duan W; Kerns K; Sousa E; He T; Logan A; Lee D; Li D; Zhou Y; Bernardo B; Joyce A; Kavosi M; O'Hara DM; Clark T; Guo J; Giragossian C; Stahl M; Calle RA; Kriz R; Somers W; Lin L
Sci Rep; 2018 Mar; 8(1):4241. PubMed ID: 29523796
[TBL] [Abstract][Full Text] [Related]
16. Pharmacologic Effects of FGF21 Are Independent of the "Browning" of White Adipose Tissue.
Véniant MM; Sivits G; Helmering J; Komorowski R; Lee J; Fan W; Moyer C; Lloyd DJ
Cell Metab; 2015 May; 21(5):731-8. PubMed ID: 25955208
[TBL] [Abstract][Full Text] [Related]
17. Increased responses to the actions of fibroblast growth factor 21 on energy balance and body weight in a seasonal model of adiposity.
Murphy M; Samms R; Warner A; Bolborea M; Barrett P; Fowler MJ; Brameld JM; Tsintzas K; Kharitonenkov A; Adams AC; Coskun T; Ebling FJ
J Neuroendocrinol; 2013 Feb; 25(2):180-9. PubMed ID: 22958332
[TBL] [Abstract][Full Text] [Related]
18. Pharmacologic stimulation of central GLP-1 receptors has opposite effects on the alterations of plasma FGF21 levels induced by feeding and fasting.
Nonogaki K; Kaji T; Yamazaki T; Murakami M
Neurosci Lett; 2016 Jan; 612():14-17. PubMed ID: 26683903
[TBL] [Abstract][Full Text] [Related]
19. Long-acting FGF21 has enhanced efficacy in diet-induced obese mice and in obese rhesus monkeys.
Véniant MM; Komorowski R; Chen P; Stanislaus S; Winters K; Hager T; Zhou L; Wada R; Hecht R; Xu J
Endocrinology; 2012 Sep; 153(9):4192-203. PubMed ID: 22798348
[TBL] [Abstract][Full Text] [Related]
20. Fibroblast growth factor 21: a novel metabolic regulator with potential therapeutic properties in obesity/type 2 diabetes mellitus.
Dostálová I; Haluzíková D; Haluzík M
Physiol Res; 2009; 58(1):1-7. PubMed ID: 19331512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
